ReviewJournal of the Chinese Medical Association : JCMA2020
House dust mite-specific immunotherapy alters the natural course of atopic march.
Review in Journal of the Chinese Medical Association : JCMA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- The Effectiveness of Allergen Immunotherapy in Adult Patients with Atopic Dermatitis Allergic to House Dust Mites.Medicina (Kaunas, Lithuania) · 2022Trial
- Safety and Effectiveness of Subcutaneous Immunotherapy with a Glutaraldehyde-Polymerized Mite Allergen Extract in Adults and Children with Allergic Rhinitis with or Without Asthma Due toDiseases (Basel, Switzerland) · 2026Article
- Comorbidity of Allergic Asthma and Rhinitis and High Allergen-Specific IgE are Risk Factors for Systemic Reactions to House Dust Mite Immunotherapy in Children.Journal of asthma and allergy · 2026Article
- Clinical outcomes of allergen immunotherapy in children in Latin America: Treatment with polymerized allergen extracts ofThe World Allergy Organization journal · 2025Article
- Identifying Causes of Subcutaneous Immunotherapy Non-Adherence in Patients with Allergic Rhinitis: A Cross-Sectional Study.Patient preference and adherence · 2025Article
- Article
- Efficacy and safety of subcutaneous immunotherapy with a mixture of glutaraldehyde-modified extracts ofThe World Allergy Organization journal · 2022Article
- Effectiveness and safety of oral lactococci-based vaccine encoding triple common allergens to prevent airway allergy in mice.PloS one · 2021Article
- [Systemic reactions to subcutaneous immunotherapy for bronchial asthma and/or allergic rhinitis in children and their risk factors].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2020Article
- Allergen Immunotherapy in Pediatric Asthma: A Pragmatic Point of View.Children (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergen immunotherapy (AIT) is an effective treatment for patients with allergic diseases; it has been shown to modify the underlying cause of the disease. The house dust mite (HDM) is a major perennial allergen source and a significant cause of allergic-related diseases such as allergic rhinitis, asthma, and atopic dermatitis. HDM allergen is an important factor in the pathogenesis of allergic diseases. Sensitization to HDM allergen often occurs early in life and appears to play an important role in the progression from allergic rhinitis to asthma in children. The role of HDM AIT results in immunologic tolerance, provides an alternative option for treating HDM allergy through targeting the mechanisms of allergic reaction, and creates a long-term benefit. There are two forms of testing for aeroallergen, either detect by skin testing or by in vitro IgE assays. Both subcutaneous immunotherapy and sublingual immunotherapy are effective in the treatment of allergic diseases. In the future, new forms of allergen extracts can help improve safety and efficacy of AIT. Novel approaches to immunotherapy currently being explored include the use of adjuvants, allergen-derived peptides, modified recombinant allergen vaccines, and gene-specific immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.